|
Mr. Lanphier is the founder of Sangamo BioSciences, Inc. and has served as President, Chief Executive Officer and a member of the Board of Directors since the company’s inception in 1995. He has over 20 years of experience in the pharmaceutical and biotechnology industries. Before founding Sangamo, from 1992 to 1997, he was associated with Somatix Therapy Corporation, a leading gene therapy company, in positions including EVP, Commercial Development and Chief Financial Officer. Prior to Somatix, Mr. Lanphier was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he was VP of Corporate Development at Biotherapeutics, Inc., and served in the same capacity at Synergen, Inc. from 1984 to 1986. Before joining Synergen, he was employed by Eli Lilly and Company (NYSE: LLY) in the strategic business planning-biotechnology group. Mr. Lanphier is a director of the Biotechnology Industry Organization (BIO) and a member of its Emerging Companies Section. He is also a member of the Board of Directors of Cengent Therapeutics, Inc. and Cell ExSys, and was recently appointed to the board of The Biotechnology Institute, a national nonprofit organization dedicated to education and research about the impact of biotechnology. Mr. Lanphier holds a BA in biochemistry from Knox College. Mr. Bonsal and Dr. Goelet developed a relationship with Mr. Lanphier when Sangamo BioSciences, Inc. (NASDAQ: SGMO) acquired Gendaq Ltd, one of the historical investments described in Historical Investment Activity and Performance. | 